Nucleic Acid Isolation and Purification Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Nucleic Acid Isolation and Purification Market is segmented By Product Type (Kits, Reagents, Instruments), By Technology (Reagent-Based Isolation and Purification, column-based Isolation and Purification, Magnetic Bead-Based Isolation and Purification, Other Technologies), By End Users (Academic and Government Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals, and Diagnostic Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

Nucleic Acid Isolation and Purification Market Overview

Nucleic Acid Isolation and Purification Market is expected to grow at a CAGR of 4.8% during the forecasting period (2024-2031).

Nucleic acid isolation and purification are a set of techniques used for the extraction and purification of DNA and RNA for downstream applications. It is part of recombinant DNA techniques.

The isolation process includes mechanical and chemical disruption and enzymatic digestion, while purification involves a combination of extraction/precipitation, chromatography, centrifugation, electrophoresis, and affinity separation. This technique has wide applications in genetic engineering, life science research, forensics, molecular diagnostics, and diagnostic tests of many STDs, congenital anomalies, cancer research.

Nucleic Acid Isolation and Purification Market Summary

For More Insights about the Market Request Free Sample

Nucleic Acid Isolation and Purification Market Dynamics

According to the US Department of Health & Human Services, in 2016, there were around 36.7 million people worldwide living with HIV AIDS, out of these, 2.1 million were less than 15 years old. Furthermore, according to the World Health Organization (WHO), around 500 million people are estimated to have genital infections, and around 290 million women acquire human papillomavirus (HPV) infection every year globally. All STDs can be diagnosed through nucleic acid isolation procedures.

Drivers

The market is driven by advancements in molecular diagnostics, increasing the prevalence of genetic disorders, cancer, infectious diseases, and STDs, an increase in government funding for research, and rising healthcare expenditures.

Rapid technological advancements in DNA Recombinant Techniques like polymerase chain reaction have helped clinical biologists to use nucleic isolation in blood screening, detection of infectious diseases, genetic disorders, oncology, and STDs. These advanced technologies are user-friendly and helpful in analyzing sample collection and obtaining accurate results.

Restraints

The high cost of automated instruments, low market penetration, and shift from proteomics to genomics are going to restrain the market in the forecast period.

Nucleic Acid Isolation and Purification Market Segmentation Analysis

The global nucleic acid isolation and purification market can be segmented by product type as Kits, Reagents, and Instruments, by technology as Reagent-Based Isolation and Purification, column-based Isolation and Purification, Magnetic Bead-Based Isolation and Purification and Other Technologies and by end-user as academic and government research institutes, pharmaceutical and biotechnology companies, Contract Research Organizations (CROs), Hospitals and Diagnostic Centers and Others.

By product type kits segment is expected to account for the largest share of the nucleic acid isolation and purification market over the period of forecast. Low cost, easy to use and applications in gene sequencing, molecular diagnostics, and gene cloning are going to fuel the Kits market.

The Magnetic Bead-Based Isolation and Purification Technique is expected to dominate the technology segment during the forecast period as this is a safe method and uses no hazardous chemicals. This method uses magnetic beads for selective binding of DNA in the presence of high concentrations of salt. At appropriate salt concentrations, the nucleic acids bind to the magnetic particles. DNA bound to magnetic beads can be easily separated from the aqueous phase using a magnet, thereby allowing rapid sample processing and fine control of solution volumes. Magnetic-based methods are ideal for the automation of high throughput processing, as they eliminate the need for centrifugation and other time-consuming steps.

Nucleic Acid Isolation and Purification Market Geographical Share

Geographically, the global nucleic acid isolation and purification market are divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.

North American market is expected to account for the largest share during the period of forecast due to significant funding in biotechnology, technological advancements, better healthcare infrastructure and facilities, faster adoption of advanced technologies such as next-generation sequencing, and government support.

The Asia Pacific is slated to emerge as the fastest growing regional market owing to rising healthcare expenditure, rapidly expanding economies, lower manufacturing costs, favorable government investments in the life sciences sector, and increasing government financing in research projects. Growing demand for quality healthcare is also an important factor in boosting the regional market.

Nucleic Acid Isolation and Purification Market Companies

Some of the major key players in the market are MP Biomedicals, Illumina, Inc., General Electric Company, Sigma-Aldrich, F.Hoffman-La Roche AG, Bio-Rad Laboratories, Promega operation, Danaher Corporation, Agilent Technologies, and ThermoFisher Scientific.

1. In November 2018, Illumina, Inc. acquired Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction.
2. In August 2018, Illumina, Inc.’s MiSeq™Dx Sequencing System received the approval certificate from the China National Drug Administration (CNDA).
3. In May 2018, Agilent Technologies Inc. acquired Lasergen, Inc. for $105 million. The collaboration aims to develop next-generation sequencing workflow solutions for clinical applications.
4. In January 2018, Illumina, Inc. launched iSeq™ 100 Sequencing System. The new, next-generation sequencing (NGS) system delivers exceptional data accuracy, at a low capital cost.
5. In January 2018, Illumina, Inc., and KingMed Diagnostics formed an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing (NGS) technology.